InvestSMART

Entropy Neurodynamics Limited (ASX:ENP)

ALERT: Price-sensitive ASX Announcement for ENP
Current share price for ENP : $0.037 0.005 (15.63%)+
Announcement
Release
2 Jun 2026 8:56AM
Price at Release
$0.032
Full Release
download
Summary
Entropy Neurodynamics Limited has successfully completed the dosing of the first cohort in its Phase 2 clinical trial for TRP-8803, an IV-infused psilocin formulation, targeting Binge Eating Disorder (BED). The trial involved six participants, each receiving two doses of TRP-8803, with results indicating a controlled and reproducible psychedelic response. Following the completion of Cohort 1, the study will undergo a review by the Data and Safety Monitoring Board before progressing to Cohort 2. The trial aims to demonstrate the advantages of IV-infused psilocin over oral therapies, promising rapid onset and controlled treatment sessions. Topline results from Cohort 1 are expected in July 2026, which will guide the next phase of the study.
Key Points
  • Cohort 1 dosing completed in Phase 2 BED study evaluating TRP-8803
  • All six participants successfully received both administrations of TRP-8803
  • A controlled and reproducible psychedelic response achieved by all participants
  • IV-infused psilocin offers significant advantages over oral therapies
  • Data Safety and Monitoring Board to review Cohort 1 safety data
  • Five of six participants for Cohort 2 have been enrolled
  • Topline Cohort 1 results expected in July 2026
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.